Physician profile
Mohammad J Shafi
NPI 1831197433
$1,962.11
in general payments reported to CMS, 2019-2025
18 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $29.66 · 2021: $325 · 2022: $38.10 · 2023: $201 · 2024: $516 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188 · Education: $45.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.74 |
| Education | $45.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.05 | 2019-2023 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $176.57 | 2023-2025 | |
| Travere Therapeutics, INC. | $165.48 | 2024-2025 | |
| Akebia Therapeutics INC | $158.35 | 2019-2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $142.03 | 2019 | |
| Amgen INC. | $135.00 | 2019-2025 | Tavneos, Krystexxa |
| Opko Pharmaceuticals, LLC | $134.16 | 2019-2024 | Rayaldee |
| Nxstage Medical, INC. | $124.99 | 2025 | Nxstage System One |
| Aurinia Pharma U.S., INC. | $121.91 | 2021 | |
| Lilly USA, LLC | $121.50 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $121.37 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $107.99 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $94.99 | 2021 | |
| Shire North American Group INC | $45.53 | 2019 | |
| Kyowa Kirin, INC. | $25.30 | 2023 | Crysvita |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.00 | 2024 | Jardiance |
| Novo Nordisk INC | $19.47 | 2025 | Ozempic |
| Daiichi Sankyo INC. | $19.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.